Technical Analysis for HUMA - Humacyte, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 4.61 | 1.54% | 0.07 |
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | 1.54% | |
| Wide Bands | Range Expansion | 1.54% | |
| Gapped Up | Strength | 1.54% | |
| Overbought Stochastic | Strength | 1.54% | |
| Wide Bands | Range Expansion | 4.54% | |
| Gapped Up | Strength | 4.54% | |
| Overbought Stochastic | Strength | 4.54% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Up 3% | about 17 hours ago |
| Up 2% | about 17 hours ago |
| Up 1% | about 17 hours ago |
| Bullish 180 Entry | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 05/10/2024
Humacyte, Inc. Description
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Health Sciences Pharmacy Diabetes Surgery Health Care FDA Regenerative Medicine Breakthrough Therapy Chronic Condition Hemodialysis Bypass Transplantation Medicine Regenerative Medicine Advanced Therapy Heart Surgery Peripheral Artery Disease Peripheral Arterial Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.858 |
| 52 Week Low | 1.96 |
| Average Volume | 1,483,154 |
| 200-Day Moving Average | 3.15 |
| 50-Day Moving Average | 3.51 |
| 20-Day Moving Average | 3.75 |
| 10-Day Moving Average | 4.21 |
| Average True Range | 0.29 |
| RSI (14) | 74.75 |
| ADX | 31.95 |
| +DI | 36.47 |
| -DI | 12.07 |
| Chandelier Exit (Long, 3 ATRs) | 3.88 |
| Chandelier Exit (Short, 3 ATRs) | 3.68 |
| Upper Bollinger Bands | 4.88 |
| Lower Bollinger Band | 2.61 |
| Percent B (%b) | 0.88 |
| BandWidth | 60.63 |
| MACD Line | 0.33 |
| MACD Signal Line | 0.23 |
| MACD Histogram | 0.0987 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.96 | ||||
| Resistance 3 (R3) | 4.96 | 4.86 | 4.90 | ||
| Resistance 2 (R2) | 4.86 | 4.77 | 4.85 | 4.88 | |
| Resistance 1 (R1) | 4.73 | 4.71 | 4.80 | 4.73 | 4.86 |
| Pivot Point | 4.63 | 4.63 | 4.66 | 4.62 | 4.63 |
| Support 1 (S1) | 4.50 | 4.54 | 4.57 | 4.50 | 4.36 |
| Support 2 (S2) | 4.40 | 4.48 | 4.39 | 4.34 | |
| Support 3 (S3) | 4.27 | 4.40 | 4.32 | ||
| Support 4 (S4) | 4.27 |
